Lupus nephritis: Keeping the wolf at bay

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 1, 2013, Pages 136-137

  Radhakrishnan, Jai ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AZATHIOPRINE; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 84872202626     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09500912     Document Type: Article

References (3)

1. Trager J, Ward MM: Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 13: 345-351, 2001.
2. Boumpas DT, Austin HAI III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992.
3. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009.